Zobrazeno 1 - 10
of 182
pro vyhledávání: ''
Autor:
Fumio Nagashima, Shun Kaneko, Daisuke Naruge, Takashi Furuta, Yuki Minowa, Kirio Kawai, Naohiro Okano, Ryohei Hirano, Takaaki Kobayashi, Hiromi Shibasaki, Sayuri Endo, Akitomo Yokokawa, Hideaki Ayukawa, Junji Furuse
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 46:317-324
Irinotecan (CPT-11) is metabolized to an active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) by carboxylesterase (CES). SN-38 is then converted to the inactive metabolite SN-38 glucuronide (SN-38G) by glucuronosyltransferase 1A1 (UGT1A1). Geneti
Autor:
Agnieszka Karbownik, Joanna Stanisławiak-Rudowicz, Michał Romański, Anna Stachowiak, Edyta Szałek, Edmund Grześkowiak
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objective Sorafenib is an oral, multikinase inhibitor with established single-agent activity in several tumor types. Sorafenib was moderately transported by P-glycoprotein (P-gp) and more efficiently by breast cancer resistance protein
Autor:
Awodayo O. Adepiti, Ayorinde Adehin, Oluseye O. Bolaji, Babatunde Ayodeji Adeagbo, Anthony A. Elujoba
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 45:81-88
MAMA decoction (MD) is an antimalarial product prepared from the leaves of Mangifera indica L. (Anacardiaceae), Alstonia boonei De Wild (Apocynaceae), Morinda lucida Benth (Rubiaceae) and Azadirachta indica A. Juss (Meliaceae). A previous report show
Autor:
Qian Li, Chun Ye Zhang, Yao Chang Xu, Jing Quan Dai, Sylvia Zhao, Jiang Wei Zhang, Feng He, Ji Yue Jeff Zhang, Hui Xin Wan, Hai Bing Deng, Hong Ping Yu, Qian Gang Zheng
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 44:669-680
MET401 is a potent and selective c-Met inhibitor with a novel triazolopyrimidine scaffold. The aim of this study was to determine the pharmacokinetic profile of MET401 in preclinical species, and to identify the metabolic soft spot and enzyme involve
Publikováno v:
Eur J Drug Metab Pharmacokinet
BACKGROUND AND OBJECTIVES: Dichotomization of pharmacokinetic exposure measures in exposure–response relationship studies provides results that are interpretable in clinical care. Several methods exist in the literature on how to define the cut-off
Autor:
Philip D. Hansten
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 43:495-508
Tamoxifen is a prodrug, and most of the therapeutic effect in treating breast cancer stems from its metabolite, endoxifen. Since cytochrome P450 (CYP) 2D6 is the most important enzyme in the production of endoxifen, drugs that inhibit CYP2D6 would be
Autor:
Mwila Mulubwa, Pierre Mugabo
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 44(4)
Pyrazinamide, a drug used in the regimen for the treatment of drug-sensitive tuberculosis, is also used for the treatment of multidrug-resistant tuberculosis (MDR-TB). We aimed to describe the population pharmacokinetics of pyrazinamide and its major
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 44(2)
It was recently proposed that CYP-mediated drug–drug interactions (DDIs) of vonoprazan with clopidogrel and prasugrel can attenuate the antiplatelet actions of the latter two drugs. Clopidogrel is metabolized to the pharmacologically active metabol
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 44(2)
Background and Objective: SUBA-itraconazole and Sporanox are two oral formulations of itraconazole. Drug–drug interactions with omeprazole have been previously reported; however, mechanistic understanding of the pharmacological and physiological in
Autor:
Włodzimierz Płotek, Agnieszka Karbownik, Agnieszka Bienert, Magdalena Cerbin-Koczorowska, Anna Wolc, Edmund Grześkowiak, Tomasz Grabowski
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 42:489-498
Paracetamol is one of the most common analgesics and antipyretics applied in health care. The aim of the study was to investigate the influence of the time-of-day administration on the paracetamol pharmacokinetics and its penetration into aqueous hum